August 11, 2020 Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on Business Operations
August 07, 2020 Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study
August 06, 2020 Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R/R FL
August 05, 2020 Fusion Pharmaceuticals To Present At The 2020 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2020 Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma
August 04, 2020 Strongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 04, 2020 GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital